Abstract
MONOCLONAL antibodies are potentially useful therapeutic agents in a variety of immunologically mediated diseases, offering the theoretical advantage of selective attack on cells implicated in the immunopathogenesis of these disorders. Antibodies to surface markers on lymphocytes, particularly T cells, have already demonstrated efficacy both in animal models and in clinical allograft rejection.1 2 3 For this purpose, monoclonal antibodies can be used either to block vital receptors for antigen, adhesion, or growth factors or to block target cells by harnessing the various natural effector systems (complement and accessory cells) that are activated by the Fc regions of cell-bound antibodies. The optimal use . . .
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
